Flutiform in Treatment of Patients With Asthma in Daily Clinical Practice.
NCT02811315 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2018-11-16
Summary
The objective of the study is to evaluate the effect of frequency of use with a spacer on asthma control in Dutch patients with asthma during their daily clinical practice over 12 weeks treatment.
Conditions
Interventions
- OTHER
-
Observational. Non interventional study
Observational. Non interventional study
Sponsors & Collaborators
-
Mundipharma Pharmaceuticals B.V.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-07-31
- Primary Completion
- 2016-12-15
- Completion
- 2016-12-15
More Related Trials
-
A Study of the Bronchodilator Effect of Formoterol Fumarate Used in Combination With Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P06476 AM2)
NCT01258803 ·Status: COMPLETED ·Phase: PHASE2
-
New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) in Patients With Asthma
NCT00394121 ·Status: COMPLETED ·Phase: PHASE3
-
Study in Patients With Asthma
NCT00215410 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma
NCT01436071 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Pharmacology Study of CHF1535 pMDI 50/6 µg Versus The Free Combination In Asthmatic Children 5-11 Years Old
NCT01848769 ·Status: COMPLETED ·Phase: PHASE2
-
A Pharmacokinetic/Pharmacodynamic Inhaler Comparison Study in Healthy Volunteers
NCT02403713 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Assess Airway Inflammation Effects of FlutiForm® pMDI Low and High Dose in Adults With Mild to Moderate Asthma
NCT00995800 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating the Efficacy and Safety of Fluticasone Furoate in the Treatment of Asthma in Adults and Adolescents
NCT01431950 ·Status: COMPLETED ·Phase: PHASE3
-
Efficiency Control of Fluticasone/Formoterol K-haler (Medium Strength) vs ICS/LABA (High Strength) in Asthma Patients
NCT04271839 ·Status: WITHDRAWN ·Phase: PHASE4
-
Study in Patients With Asthma
NCT00215358 ·Status: COMPLETED ·Phase: PHASE2
-
Knemometry Study to Compare the Systemic Safety of Flutiform pMDI, Fluticasone pMDI and Beclometasone Autohaler in Paediatric Subjects Aged 5 to Less Than 12 Years.
NCT02063139 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma
NCT00394199 ·Status: COMPLETED ·Phase: PHASE3
-
Small Airway Function of Fluticasone/Formoterol (Flutiform®) and Fluticasone/Salmeterol
NCT02491970 ·Status: TERMINATED ·Phase: PHASE4
-
A Dose-ranging Study of Fluticasone Furoate (FF)
NCT01563029 ·Status: COMPLETED ·Phase: PHASE2
-
Study of FlutiForm® Versus Fluticasone Plus Formoterol in Adult Subjects With Severe Asthma
NCT00734318 ·Status: COMPLETED ·Phase: PHASE3
-
Study of FLUTIFORM® VS Seretide® in Paediatric Subjects With Asthma
NCT00475813 ·Status: COMPLETED ·Phase: PHASE3
-
Study in Patients With Asthma
NCT00215397 ·Status: COMPLETED ·Phase: PHASE2
-
Study in Patients With Asthma
NCT00215371 ·Status: COMPLETED ·Phase: PHASE2
-
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
NCT01225913 ·Status: RECRUITING ·Phase: PHASE4
-
Fine Particle pMDI Formoterol/Beclomethasone in Asthmatics With and Without Spacer: Comparative Efficacy Evaluation
NCT01453881 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma
NCT02141854 ·Status: COMPLETED ·Phase: PHASE3
-
Assessment of Airway Responsiveness and Treatment Efficacy in Asthmatics
NCT02574975 ·Status: UNKNOWN ·Phase: PHASE4
-
Symbicort Single Inhaler Therapy for Asthma in a General Practice Setting
NCT00235911 ·Status: COMPLETED ·Phase: PHASE3
-
Randomised Study Comparing the Effects of Inhaled FF/GW642444M Combination, FF and GW642444M on an Allergen Induced Asthmatic Response
NCT01128595 ·Status: COMPLETED ·Phase: PHASE2
-
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
NCT03086460 ·Status: COMPLETED ·Phase: PHASE2